DOI: 10.12890/2020_001708

Eribulin and Confusion: A Previously Unknown Drug Side-Effect

Authors

  • Abu Baker Sheikh Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
  • Abhilash Perisetti Department of Gastroenterology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  • Nismat Javed Department of Internal Medicine, Shifa College of Medicine, Islamabad, Pakistan
  • Rahul Shekhar Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA

drabubakersheikh@gmail.com

Keywords

Eribulin, encephalopathy, breast cancer

Abstract

Eribulin is an antineoplastic agent used in advanced breast cancer refractory to anthracycline and taxane treatment regimens. A wide variety of side effects with unclear mechanisms have been noted, but encephalopathy has not been widely reported. Here we describe the case of a middle-aged woman treated with eribulin for advanced breast cancer who subsequently developed central nervous system drug-induced toxicity but improved promptly with steroid administration.

View the entire article

Downloads

Published

2020-06-09

Issue

Vol. 7 No. 9 (2020)

How to Cite

1.
Sheikh AB, Perisetti A, Javed N, Shekhar R. Eribulin and Confusion: A Previously Unknown Drug Side-Effect. EJCRIM [Internet]. 2020 Jun. 9 [cited 2026 Nov. 3];7(9). Available from: https://ejcrim.com/index.php/ejcrim/article/view/1708

Most read articles by the same author(s)